Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial

Chinese Medical Journal

Volumn 121, Issue 7, 2008, Pages 615-619

  Lü, Liang Jing ^a   Teng, Jia Lin ^a   Bao, Chun De ^a   Han, Xing Hai ^b   Sun, Ling Yun ^c   Xu, Jiang Hua ^d   Li, Xing Fu ^e   Wu, Hua Xiang ^f  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e SHANDONG UNIVERSITY   (China)

^f ZHEJIANG UNIVERSITY   (China)

Author keywords

Arthritis; Randomized controlled trial; Rheumatoid; T 614

Indexed keywords

C REACTIVE PROTEIN; IGURATIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STEROID; ANTIRHEUMATIC AGENT; BENZOPYRAN DERIVATIVE; SULFONAMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FACE EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAND EDEMA; HUMAN; HYPERHIDROSIS; INFECTION; INSOMNIA; LEG EDEMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; VOMITING; AGED; MALE; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BENZOPYRANS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SULFONAMIDES;

EID: 46449101583     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804010-00008     Document Type: Article

References (12)

1. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharmacological studies on T-614, a novel anti-inflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/1 mice. Int J Immunother 1993; 9: 69-78.
2. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999; 133: 566-574.
3. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells. J Rheumatol 2001; 28: 2591-2596.
4. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology 2003; 42: 1365-1371.
5. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 2007; 17: 1-9.
6. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 10-16.
7. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety. Ann Intern Med 1987; 107: 358-366.
8. Williams HJ, Ward JR, Dahl SL, Clegg DO, Willkens RF, Oglesby T, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988; 31: 702-713.
9. Chunde B, Wengqun H, Shunle C. Safety and effectiveness of leflunomide in patients with rheumatoid arthritis: results of a randomized, double-blind, controlled Study. Chin Rheumat J (Chin) 2000; 4: 44-46.
10. Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, et al. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial. Chin Med J 2003; 116: 1228-1234.
11. Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-1055.
12. Kremer JM, Alarcon GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-328.